Experts highlight growing role of treatment intensification for metastatic castration-sensitive prostate cancer

During an OncLive Peer Exchange, prostate-cancer specialists examined how treatment intensification is reshaping management of metastatic castration-sensitive prostate cancer.

They noted that androgen-deprivation therapy alone no longer provides optimal outcomes for many patients, citing several phase-3 trials that showed added benefit when therapy is intensified beyond ADT.

Because no randomized head-to-head comparisons exist among androgen-receptor pathway inhibitors, clinicians must tailor choices to individual patients, and real-world evidence should complement trial data in decision-making.